Selank
Selank is a synthetic analog of the immunomodulatory peptide tuftsin, studied for its anxiolytic-like and nootropic effects in preclinical models.
Part of KYIN Peptides' standard catalogue — see the product page for pricing.
What Is Selank?
Selank's starting point is tuftsin, an immune-system peptide first described by Victor Najjar at Tufts University in the 1970s, known for enhancing the activity of macrophages and neutrophils. Tuftsin had an obvious practical problem, though: it breaks down in the bloodstream within seconds, which made it impractical to study or use as anything beyond a short-lived signal. In the 1990s, a research team led by Nikolai Myasoedov at the Institute of Molecular Genetics of the Russian Academy of Sciences set out to fix that, appending a stabilizing tripeptide — proline-glycine-proline — onto tuftsin's C-terminus. The resulting heptapeptide, Selank, kept tuftsin's original immunomodulatory activity but gained a second, unexpected property: pronounced effects on neurological research models. See its full discovery history.
Research Focus
Selank's research use today tracks the neurotropic effects that emerged unexpectedly from the original tuftsin-stabilization work, rather than its original immunological starting point. It sits in KYIN's Cognitive & Nootropic category alongside Semax and Pinealon. See our Cognitive & Nootropic research overview, or how it compares to Semax.
- Anxiolytic mechanism research
- Cognitive and nootropic studies
- Neuropeptide behavior research
Clinical & Preclinical Trial Data
A published human trial (Zozulya et al., 2008; 62 patients with generalized anxiety disorder or neurasthenia, comparing 30 on Selank against 32 on the benzodiazepine medazepam) found Selank produced anxiolytic effects comparable to medazepam, plus antiasthenic and mild psychostimulant effects the benzodiazepine did not show, correlating with increased leu-enkephalin levels. Selank has been approved as a prescription pharmaceutical by Russia's Ministry of Health since 2009. That human trial data comes from Russian-language clinical literature and has not been replicated in a Western trial or independently reviewed in a Cochrane-style systematic review — real published human evidence, but outside the FDA trial pathway that governs drug approval in the United States.
Availability
Selank is part of KYIN Peptides' standard catalogue — see the product page for pricing, or contact us to order.
Selank questions
What is Selank?
Selank is a synthetic heptapeptide developed in the 1990s by Nikolai Myasoedov's team at the Institute of Molecular Genetics of the Russian Academy of Sciences, built by stabilizing the immune peptide tuftsin with a proline-glycine-proline tripeptide. It is studied for anxiolytic-like and nootropic effects in preclinical models.
Has Selank been tested in human trials?
Yes. A published human trial (Zozulya et al., 2008; 62 patients with generalized anxiety disorder or neurasthenia, comparing 30 on Selank against 32 on the benzodiazepine medazepam) found Selank produced anxiolytic effects comparable to medazepam, plus antiasthenic and mild psychostimulant effects the benzodiazepine did not show. Selank has been approved as a prescription pharmaceutical by Russia's Ministry of Health since 2009.
Does KYIN Peptides sell Selank?
Yes — Selank is part of our standard catalogue. See the product page for pricing.
Interested in Selank?
See pricing and order on the product page, or browse our other cognitive & nootropic peptides.